Look to see MYRX start trending up in anticipation of the ASCO conference in early June. Additionally, from a TA standpoint, this is trading at support which is also near its 52-week low. Also, the chart is a descending wedge trading near its apex. Look to see this "pop" in the other direction and start trending up based on that very soon! Great entry point!!!!!!!!
<<June 4-8, 2010, the Company expects to report results from two ongoing Phase 2 trials of Azixa(TM) (MPC-6827), in metastatic melanoma in combination with temozolomide and in recurrent glioblastoma ("GBM") in combination with carboplatin, at the American Society for Clinical Oncology ("ASCO") meeting in Chicago. In addition, an abstract describing the updated result of the Phase 1 clinical trial of MPC-3100 will be published on www.asco.org and www.jco.org in a fully searchable format.>>
Also, Javelin officially terminated the merger agreement with Myriad, and Hospira agreed to pay a $4.4 million breakup fee to Myriad. The merger is not going to happen, however $4.4 million will certainly do nothing but help Myriad's finances out even more!!